Clinical trial · NCT04889742 · NOT_YET_RECRUITING · PHASE2
Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors
Sponsor: Charite University, Berlin, Germany
Summary
This study investiagates deep-regional or superficial hyperthermia to enhance radiotherapy or chemoradiation in patients that suffer recurrent disease after previous radiotherapy.
Interventions
- loco-regional hyperthermia · DEVICE
loco-regional hyperthermia by the use of microwave, capacitive, or superficial hyperthermia devices.
Published eligibility criteria
Verbatim from the registry. Only the site can decide how these apply to a specific patient.
Inclusion Criteria: * prior radiotherapy of the treatment side with a treatment dose \> 30 Gray (Gy) EQD2 (calculated with alpha/beta value of 9) * local/ regional / or oligometastatic tumor recurrence. Maximum number of three macroscopic tumor lesions with at least one of them receiving prior radiotherapy * macroscopic tumor recurrence * side of recurrence is amenable to hyperthermia (abdomen, pelvis, extremities, spine, cervical lymphnodes) * planned re-irradiation dose of at least 40 Gy EQD2 (calculated with alpha/beta value of 9) Exclusion Criteria: * \>3 macroscopic tumor lesion * brain metastases * recurrence is amenable to local ablative radiotherapy (brachytherapy or stereotactic radiotherapy) * recurrence region is not amenable to hyperthermia (lung, liver, mediastinum) * contraindications for hyperthermia (serious cariovascular disease, ICD or larger implants at the treatment site) * psychiatric disorders that impede proper informed consent * serious comorbidities with very limited prognosis quo ad vitam
Sites (1)
- Klinik für Radioonkologie und Strahlentherapie, Berlin, Germany
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors. Registry data refreshed at most hourly; last update posted 2023-12-26.